| Filed On | Filing |
|---|---|
| 27 Aug 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On April 23, 2026, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) disclosing that Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, would transition to a new ... |
| 25 Feb 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On December 17, 2025, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K announcing the election of Simon Dingemans as a director of the Company effective January 2, 2026. The prior report did not include the committees of ... |
| 25 Feb 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On December 4, 2025, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K announcing the election of Sanjeev Mehra as a director of the Company effective December 4, 2025. The prior report did not include the committees of th... |
| 18 Aug 2021 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On July 19, 2021, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K announcing the election of Dr. John Carethers as a director of the Company effective July 15, 2021. The prior report did not include the committees of the... |
| 18 Aug 2021 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On May 17, 2021, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K announcing the election of Lan Kang as a director of the Company effective May 14, 2021. The prior report did not include the committees of the Board of Di... |
| 05 Nov 2019 |
8-K/A: Results of Operations and Financial Condition
Net sales of $1.50 billion, net income of $22.1 million, adjusted EBITDA of $250.8 million |
Loading...